Celldex's Barzolvolimab Meets Phase 3 Goals In Chronic Hives Studies; Stock Down

Celldex (CLDX) reported positive topline results from two Phase 3 studies of Barzolvolimab, with the treatment meeting the primary endpoint and all key secondary endpoints in patients with chronic spontaneous urticaria, also known as chronic hives.